Literature DB >> 22760259

Association of apoE gene expression and its gene polymorphism with nephrotic syndrome susceptibility: a meta-analysis of experimental and human studies.

Tian-Biao Zhou1, Yuan-Han Qin, Hui-Ling Xu.   

Abstract

Apolipoprotein E (apoE) is a major protein in the lipoprotein transport system that plays a well established role in lipids metabolism. apoE gene contains three potential alleles: ε2, ε3 and ε4, forming six genotypes: ε2ε2, ε2ε3, ε2ε4, ε3ε3, ε3ε3 and ε4ε4. The disorder of lipids metabolism is an important feature for nephrotic syndrome (NS). There were some investigations reporting that apoE and its gene polymorphism was associated with NS susceptibility. However, the mechanism was unclear and the association was still controversial. This meta-analysis was performed to evaluate the association between apoE and NS risk in experimental and human studies. A predefined literature search and selection of eligible relevant studies were performed to collect the data from electronic databases, and eligible investigations were synthesized using meta-analysis method. In experimental models, twelve comparisons were included and a definitely positive association was observed between apoE protein expression and NS susceptibility (WMD = 1.88, P < 0.00001). However, in human, there was only two studies included for meta-analysis and a positive association between apoE protein expression and NS susceptibility wasn't found (OR = 108.10, P = 0.32). Interestingly, ε3ε3, ε3ε4, ε3 and ε4 were associated with NS susceptibility (ε3ε3: OR = 0.56, P = 0.002; ε3ε4: OR = 1.91, P = 0.02; ε3: OR = 0.61, P = 0.001; ε4: OR = 1.85, P = 0.009). In conclusion, the apoE gene expression was associated with the NS susceptibility in experimental studies, and the apoE ε3ε3, ε3ε4, ε3 and ε4 were associated with the onset of NS in human studies. This study supported that the disorder of apoE was one of the possible causes for NS risk. However, more studies should be performed to investigate this relationship in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22760259     DOI: 10.1007/s11033-012-1751-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  41 in total

1.  Role of apolipoprotein E in renal damage protection.

Authors:  F Bonomini; L F Rodella; M Moghadasian; C Lonati; R Coleman; R Rezzani
Journal:  Histochem Cell Biol       Date:  2011-05-15       Impact factor: 4.304

2.  Long-term follow-up of a paediatric case of lipoprotein glomerulopathy.

Authors:  Y Koitabashi; M Ikoma; T Miyahira; R Fujita; H Mio; M Ishida; K Shimizu; H Sakaguchi
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

Review 3.  [Lipoprotein glomerulopathy: a new French case with recurrence on the transplant].

Authors:  A Djamali; J P Cristol; C Turc-Baron; I Beucler; P Baldet; G Mourad
Journal:  Presse Med       Date:  1996-05-18       Impact factor: 1.228

4.  Graded effects of proteinuria on HDL structure in nephrotic rats.

Authors:  Gregory C Shearer; John W Newman; Bruce D Hammock; George A Kaysen
Journal:  J Am Soc Nephrol       Date:  2005-03-23       Impact factor: 10.121

5.  Apolipoprotein E polymorphism in childhood nephrotic syndrome.

Authors:  Gulen Attila; Aytul Noyan; Aysun Karabay Bayazit; Esmeray Acartürk; Ali Anarat
Journal:  Pediatr Nephrol       Date:  2002-05       Impact factor: 3.714

6.  Apolipoprotein E polymorphism and clinical course in childhood nephrotic syndrome.

Authors:  Sung-Do Kim; Il-Soo Kim; Byung-Cheol Lee; Kang-Duk Choi; Joo-Ho Chung; Chun-Gyoo Ihm; Byoung-Soo Cho
Journal:  Pediatr Nephrol       Date:  2003-02-13       Impact factor: 3.714

7.  Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria.

Authors:  G L Warwick; C J Packard; T Demant; D K Bedford; J M Boulton-Jones; J Shepherd
Journal:  Kidney Int       Date:  1991-07       Impact factor: 10.612

Review 8.  Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity.

Authors:  Miho Karube; Kimimasa Nakabayashi; Yasunori Fujioka; Ken Yoshihara; Akira Yamada; Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

9.  Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  Maurizio Bruschi; Paolo Catarsi; Giovanni Candiano; Maria Pia Rastaldi; Luca Musante; Francesco Scolari; Mary Artero; Michele Carraro; Alba Carrea; Gianluca Caridi; Cristina Zennaro; Simone Sanna-Cherchi; Fabio Battista Viola; Franco Ferrario; Francesco Perfumo; Gian Marco Ghiggeri
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

10.  Renal apolipoproteins in nephrotic rats.

Authors:  H van Goor; M L van der Horst; J Atmosoerodjo; J A Joles; A van Tol; J Grond
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

View more
  6 in total

1.  Meta-analysis of the association of glutathione S-transferase T1 null/presence gene polymorphism with the risk of gastric carcinoma.

Authors:  Yuan-Biao Meng; Xiao-Yong Cai; Wen-Qi Lu; Li-Hua Yang; Ting-Qing Gan; Gregor P C Drummen
Journal:  Mol Biol Rep       Date:  2013-12-19       Impact factor: 2.316

2.  Apolipoprotein E gene E2/E2 genotype is a genetic risk factor for vertebral fractures in humans: a large-scale study.

Authors:  Shu Qi Zhang; Wei Ying Zhang; Wen Qin Ye; Ling Juan Zhang; Fan Fan
Journal:  Int Orthop       Date:  2014-06-01       Impact factor: 3.075

3.  Apolipoprotein E polymorphism is associated with lower extremity deep venous thrombosis: color-flow Doppler ultrasound evaluation.

Authors:  Shuangli Zhu; ZhiGang Wang; XiaoPing Wu; Yan Shu; DunXiang Lu
Journal:  Lipids Health Dis       Date:  2014-01-24       Impact factor: 3.876

Review 4.  Apolipoprotein E gene variants on the risk of end stage renal disease.

Authors:  Cheng Xue; Wei Nie; Dan Tang; Lujiang Yi; Changlin Mei
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

5.  Apolipoprotein E polymorphism and the risk of intracranial aneurysms in a Chinese population.

Authors:  Hao Liu; Ping Mao; Changhou Xie; Wanfu Xie; Maode Wang; Haitao Jiang
Journal:  BMC Neurol       Date:  2016-01-29       Impact factor: 2.474

6.  Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function.

Authors:  Mauro Sergio Martins Marrocos; Andrei Alkmin Teixeira; Beata Marie Quinto; Silmara de Melo Carmona; Mariana Kuniyoshi; Cassio Jose Rodrigues; Maria Aparecida Dalboni; Silvia Manfredi; Maria Eugênia Canziani; Marcelo Costa Batista
Journal:  Lipids Health Dis       Date:  2016-01-20       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.